MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$2.05 +2.02%

+$0.08 today

Market cap
$131.01M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.57M

Average 0.98M

MGNX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

MacroGenics, Inc.NASDAQ: MGNX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 46.0%

Gross margin was 46.0% in Q1 FY2026, up 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 69.9%, up 7.9 pp year over year. Over 3 fiscal years it narrowed by 24.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
46.0%-25.3 pp QoQ
Last fiscal yearDec 2025
71.1%-20.6 pp YoY
LTMMar 2026
69.9%+7.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.4 pp——
1 year-20.6 pp——
3 years-24.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
71.1%
Year-over-year change
-20.6pp

Gross Margin vs competitors

How MGNX compares with its peers on the latest reported figures

  • MGNX's LTM Mar 2026 gross margin of 69.9% is the 5th highest of the 9 companies compared; the peer median is 45.0%.
  • Its year-over-year change of +7.9 pp is the 3rd highest of 8, against a peer median of -0.5 pp.
  • Over three fiscal years its change of -24.0 pp compares with a peer median of -4.1 pp.
MGNX Competitors Peer median
Gross Margin for MGNX and competitors
Company Period LTM level YoY 3-year change
CNTBConnect Biopharma Holdings LimitedFY2025100.0% +0.0 pp—
COYACoya Therapeutics, Inc.LTM Mar 202699.8% +378.1 pp—
OVIDOvid Therapeutics Inc.LTM Mar 202699.5% -0.5 pp-4.1 pp
WHWKWhitehawk Therapeutics IncFY202589.4% +197.4 pp+212.8 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
ORMPOramed Pharmaceuticals Inc.FY20250.7% —-99.4 pp
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
CLNNClene Inc.LTM Mar 2026-182.1% -260.9 pp-16.0 pp
IFRXInflaRx N.V.LTM Mar 2026-24646.3% -22352.6 pp—
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding MGNX) 45.0%-0.5 pp-4.1 pp

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$2.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.